Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

Sorafenib, a multi-tyrosine kinase inhibitor, kills more effectively the non-metastatic prostate cancer cell line 22Rv1 than the highly metastatic prostate cancer cell line PC3. In 22Rv1 cells, constitutively active STAT3 and ERK are targeted by sorafenib, contrasting with PC3 cells, in which these...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kharaziha, P, Rodriguez, P, Li, Q, Rundqvist, H, Björklund, A-C, Augsten, M, Ullén, A, Egevad, L, Wiklund, P, Nilsson, S, Kroemer, G, Grander, D, Panaretakis, T
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 2012
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3270278/
https://ncbi.nlm.nih.gov/pubmed/22278289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2012.1
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge